加载中
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
收盘时
US$3.36
−US$0.27 · -7.44%
盘后
US$3.36
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
日内区间
当前US$3.36
52周区间
当前US$3.36
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
29
偏贵
情绪
51
多空交织
风险
96
极高风险
动量
33
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
日内区间
当前US$3.36
52周区间
当前US$3.36
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 30.16万 USD | 16.87万 USD | 11.07万 USD | 132.14万 USD | 14.41万 USD |
| 销货成本 | 6.14万 USD | 3.66万 USD | 2.57万 USD | 36.32万 USD | 2.14万 USD |
| 毛利 | 24.03万 USD | 13.21万 USD | 8.51万 USD | 95.81万 USD | 12.26万 USD |
| 研究与开发 | 108.35万 USD | 119.1万 USD | 192.2万 USD | 51.1万 USD | 13.9万 USD |
| 销售、一般及管理费用 | 754.76万 USD | 669.59万 USD | 385.95万 USD | 279.12万 USD | 614.12万 USD |
| 营业费用 | 863.12万 USD | 788.68万 USD | 578.14万 USD | 279.12万 USD | 614.12万 USD |
| 利息收入 | 8240 USD | 3193 USD | — | — | — |
| 利息支出 | — | — | 3.88万 USD | 5.94万 USD | 8.23万 USD |
| 折旧和摊销 | 2.15万 USD | 1.51万 USD | 4254 USD | 535 USD | 537 USD |
| 营业利润 | −839.09万 USD | −775.46万 USD | −569.63万 USD | −183.3万 USD | −601.86万 USD |
| 净利润 | −822.22万 USD | −760.72万 USD | −464.87万 USD | −169.78万 USD | −607.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月31日 | 1:30 | — | — |
已生效 2026年8月31日
1:30
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
